DYRK2 is identified as a novel negative regulator of cardiomyocyte growth, suggesting it could be a therapeutic target for regulating myocardial growth.
Answers are grounded in this paper and cite their sources.
Should not change practice; hypothesis-generating for DYRK2-targeted growth modulation in cardiac disease.
The interaction of GSK-3β and its priming kinase DYRK2 regulate the activity of eIF2Bε in cardiac myocytes. DYRK2 is a novel negative regulator of cardiomyocyte growth. DYRK2 could serve as a therapeutic option to regulate myocardial growth.
No takes yet. Share an insight, caveat, or question.
Weiß et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: